LncRNAs: new players in gliomas, with special emphasis on the interaction of lncRNAs With EZH2

J Cell Physiol. 2015 Mar;230(3):496-503. doi: 10.1002/jcp.24549.

Abstract

Gliomas are the most common primary malignancy in the brain, accounting for 50-60%. Despite all the efforts of cytoreductive surgery in combination with intense chemoradiotherapy, glioma remains an incurable disease. Recent studies have shown that long noncoding RNAs (lncRNAs) are involved in the pathology of gliomas. LncRNAs are involved in many cellular processes, such as angiogenesis, invasion, cell proliferation, and apoptosis. In this review we focus on the dysregulation of lncRNAs in gliomas. We also address that epigenetic modification such as DNA methylation and microRNAs interact with lncRNAs in gliomas. In addition, the interaction of lncRNAs with signaling pathways in gliomas is discussed systematically, with particular emphasis on the interaction of lncRNAs with EZH2. Such approaches provide valuable insights into the potential future applications of lncRNAs in the treatment of gliomas.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Apoptosis / genetics
  • Cell Proliferation / genetics
  • DNA Methylation / genetics
  • Enhancer of Zeste Homolog 2 Protein
  • Glioma / genetics*
  • Glioma / pathology
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasm Invasiveness / genetics
  • Neovascularization, Pathologic / genetics
  • Polycomb Repressive Complex 2 / biosynthesis
  • Polycomb Repressive Complex 2 / genetics*
  • RNA, Long Noncoding / genetics*
  • RNA, Long Noncoding / metabolism
  • Signal Transduction

Substances

  • RNA, Long Noncoding
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb Repressive Complex 2